Navigation Links
HUYA Bioscience International and Tianjin International Joint Academy of Biotechnology and Medicine Form Alliance
Date:10/18/2011

SAN DIEGO, Oct. 18, 2011 /PRNewswire/ -- HUYA Bioscience International, a leader in globalizing China's biopharmaceutical innovations, today announced a strategic alliance with the Tianjin International Joint Academy of Biotechnology and Medicine (TJAB). The alliance will unite the strength and resources of both parties to accelerate the development of China's biomedical innovation and industrialization.

HUYA is one of the first companies to have recognized China's potential to help meet the global need for new preclinical and clinical stage compounds. The company is committed to facilitating and promoting the global development and commercialization of novel pharmaceutical products originating in China. HUYA has established a series of collaborations with leading universities and research institutions throughout China and has pioneered in-licensing both preclinical and clinical stage compounds from the country, utilizing its expertise to advance these compounds for global markets.

TJAB, a state of the art pharmaceutical research & development platform, was jointly established by the Ministry of Science and Technology, the Ministry of Commerce, the Ministry of Health, the State Food and Drug Administration, and Tianjin Municipality.  It was established with the vision of creating China's International Innovation Zone of Biotechnology and Medicine (BioMed Zone) to boost China's biomedical industry. Situated at the heart of the Tianjin Binhai New Area, TJAB  has attracted more than 100 research & development groups, focusing in the areas of infectious diseases, cancer, diabetes, and hypertension.

Under the agreement, TJAB and HUYA will collaborate to promote new drug development. HUYA will have the first opportunity to provide assistance in evaluating research and development projects conducted by enterprises residing in TJAB. HUYA will also be able to globalize select programs from TJAB through HUYA's innovative co-developme
'/>"/>

SOURCE HUYA Bioscience International
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
2. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
3. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
4. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
5. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
6. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
7. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
8. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
9. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
10. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
11. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Calif. , Aug. 31, 2015 ... flow cytometry is experiencing a rise in active ... demand in underdeveloped nations to quantitate CD4 cell ... Logo - http://photos.prnewswire.com/prnh/20150831/262206LOGO ... of the Global Flow Cytometry Market ( http://www.frost.com/nf0e ...
(Date:8/31/2015)... , Aug. 31, 2015  The departments of Drug ... today at Gaudenzia Concept 90 to raise awareness for ... crisis in Pennsylvania and help ... focus on recovery through the Building Bridges to ... are dying every day to a disease that is ...
(Date:8/31/2015)... , Aug. 31, 2015  Diplomat Pharmacy, Inc. (NYSE: ... that Phil Hagerman , Chairman & CEO, and ... conferences. Mr. Hagerman and Mr. Whelan are ... in Boston on Wednesday, September 9, ... Mr. Whelan are also scheduled to participate in the Robert ...
Breaking Medicine Technology:Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 2Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 3Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 4Pennsylvania Departments of Drug & Alcohol Programs and Health Kick-off Second Annual Building Bridges to Recovery Initiative 2Diplomat to Participate in Upcoming Investor Conferences 2
... OrbusNeich today announced that six-month clinical follow-up data show the safety ... balloon (Sequent Please®, B.Braun) followed by implantation of the company,s Genous ... , , , ... investigator-initiated, single center, all-comers POTENT ( P aclitaxel-eluting ball O on ...
... Pfizer Inc. (NYSE: PFE ) announced today that based ... be discontinuing commercial availability of Mylotarg® (gemtuzumab ozogamicin for Injection) (used for ... States and that it will be voluntarily withdrawing the new drug ... , , ...
Cached Medicine Technology:Data Show OrbusNeich's Genous™ Bio-engineered R stent™ is Safe and Effective in Combination with Drug-Eluting Balloon 2Data Show OrbusNeich's Genous™ Bio-engineered R stent™ is Safe and Effective in Combination with Drug-Eluting Balloon 3Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg® 2Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg® 3Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg® 4Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg® 5Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg® 6
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... In an ... from the Plastic and Reconstructive Surgery Global Open Journal that discusses the future of ... article discussed how, in the future, customized implants, prosthetics, and other 3-D printed tools ...
(Date:8/31/2015)... ... August 31, 2015 , ... David L. Chalnick, M.D., ... of the first doctors in the area to perform minimally invasive hip replacement ... impressive: faster recovery, decreased immediate and long-term pain, and an accelerated return to ...
(Date:8/31/2015)... Scotch Plains, NJ (PRWEB) , ... August 31, 2015 , ... ... years as an “NJ Top Doc.” , At OSSMC, Dr. Kovatis treats all surgical ... general orthopedics and traumatic injuries to the entire musculoskeletal system, excluding the spine. , ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... diagnostic services, and others—to hold down costs? , In a commentary for ... of HealthReveal, presents the concept of “clinical efficacy,” which would bind parties together ...
(Date:8/31/2015)... CA (PRWEB) , ... August 31, 2015 , ... ... the 2015 ABBY Awards, at the 16th Innovations in Healthcare(SM) Awards Event ... Adaptive Business Leaders (ABL) Organization , recognizes innovative organizations and individuals who ...
Breaking Medicine News(10 mins):Health News:Recent Article on 3-D Printing Highlights the Future of Custom Medical Solutions Using the Technology, says Beverly Hills Physicians 2Health News:Recent Article on 3-D Printing Highlights the Future of Custom Medical Solutions Using the Technology, says Beverly Hills Physicians 3Health News:NJ Top Docs Presents, Dr. David L. Chalnick! 2Health News:NJ Top Docs Presents, Dr. David L. Chalnick! 3Health News:NJ Top Docs Presents, Dr. David L. Chalnick! 4Health News:NJ Top Docs Presents, Dr. Paul Kovatis of Orthopedic Spine & Sports Medicine Center on his Five Year Anniversary as an "NJ Top Doc" 2Health News:How “Clinical Efficacy” Can Rein in Healthcare Costs 2Health News:How “Clinical Efficacy” Can Rein in Healthcare Costs 3Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 2Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 3Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 4Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 5Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 6Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 7Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 8
... 2 Rochester Medical Corporation (Nasdaq: ROCM ) ... 31, 2008.The Company reported sales of $8,436,000 for the current ... year. It also reported net income of $54,000 or ... or $.02 per diluted share for the first quarter of ...
... Calif., Feb. 2 Digirad Corporation (Nasdaq: ... and personnel and equipment leasing services that improve patient ... it has sold the assets related to three northern ... with Rancho Santa Fe, Calif.-based MD Office Solutions calls ...
... More exposure meant more symptoms, study found , , MONDAY, ... hours watching television are at higher risk for depression ... significantly greater odds of being depressed seven years later, ... television viewed, according to a report involving more than ...
... for Quality,Assurance (NCQA) has awarded Unison Health Plan of ... program through December 2011. The plan serves,more than ... is based on how well a health plan ensures ... the health,plan,s core systems and processes, but also the ...
... are heavy users of marijuana are more likely ... to a new study. Pediatric researchers found abnormalities ... regions involved in memory, attention, decision-making, language and ... concern because adolescence is a crucial period for ...
... Post-Katrina flooded homes may contain harmful levels of ... mold films, and aerosols may also have exposed residents, ... without the need for direct skin contact, according to ... (Volume 26, Number 3) of Environmental Engineering Science, a ...
Cached Medicine News:Health News:Rochester Medical Reports First Quarter Results 2Health News:Rochester Medical Reports First Quarter Results 3Health News:Rochester Medical Reports First Quarter Results 4Health News:Rochester Medical Reports First Quarter Results 5Health News:Rochester Medical Reports First Quarter Results 6Health News:Rochester Medical Reports First Quarter Results 7Health News:Rochester Medical Reports First Quarter Results 8Health News:Digirad Corporation Sells Northern California Service Hubs 2Health News:Teen TV Time Tied to Adult Depression 2Health News:Teen TV Time Tied to Adult Depression 3Health News:Unison Health Plan of Ohio Accredited by NCQA 2Health News:Heavy marijuana use may damage developing brain in teens, young adults 2Health News:Newly Described Contaminant Sources in Katrina-Flooded Homes Pose Health Risks 2
... When myocardial infarction is suspected, ... sensitive rapid assay allows rapid ... troponin T from a single ... result is available within minutes ...
The Polygraf ID multi-parametric recorder works with POLYGRAM NET analysis software to create a unique interface that combines web-style navigation, graphical presentation and intuitive design to del...
... the industry standard high intensity 300 Watt Xenon ... price. A universal turret on the front panel ... Olympus, Storz, ACMI/Circon and Wolf cable connectors., ,Front ... timer. The White Sun will quickly illuminate at ...
... is intended for determination of human NGAL ... tissue extracts or culture media., NGAL (neutrophil ... urine, as early as 2 hours after ... processes. NGAL expression in plasma or urine ...
Medicine Products: